Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $700 from $750 and keeps an Overweight rating on the shares. The firm says Q1 results reinforce need for Eylea reset and its revised estimates lower its price target However, Wells sees above-average 5-year top/bottom-line CAGR post this rebasing year. Pipeline execution is crucial for Regeneron to shift narrative away from Eylea, the firm argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Evan Seigerman’s Buy Rating on Regeneron: Overcoming Challenges with a Promising Pipeline and Undervalued Assets
- Regeneron Buy Rating: Navigating Challenges with a Promising Pipeline and Strategic Investments
- Regeneron’s Eylea Challenges Prompt Underperform Rating Amid Market Erosion and FDA Setback
- Regeneron Reports Strong Q1 2025 Financial Results
- Regeneron (REGN) Earnings Call: Growth Amid Challenges